N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide
• 化学式: C₁₈H₁₇Cl₂NO
• 分子量: 334.2
• InChiKey: YIQKGDBXOASLSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide 以95的产率得到(1R,4S)-4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺盐酸盐(1:1)
  参考文献：
  名称：

  Chem. Eur. J. 2009, 15, 3403-3410

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(4-(3,4-dichlorophenyl)-1,2-dihydronaphthalen-1-yl)acetamide 以95的产率得到N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide
  参考文献：
  名称：

  Chem. Eur. J. 2009, 15, 3403-3410

  摘要：

  DOI：

文献信息

• Preparation of chiral amides and amines
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US10011559B2

  公开（公告）日：2018-07-03

  This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.

  本发明提供了一种将肟转化为酰胺的简便方法。该工艺无需使用金属试剂。因此，在生产所需化合物的同时，不会产生大量金属废料。酰胺是酰胺和胺的有用前体。本发明提供了一种将原手性烯酰胺转化为相应的手性酰胺的工艺。在一个示例工艺中，通过使用手性氢化催化剂，在氢化过程中引入手性氨基中心。在选定的实施方案中，本发明提供了制备包括1,2,3,4-四氢-N-烷基-1-萘胺或1,2,3,4-四氢-1-萘胺亚结构的酰胺和胺的方法。
• Chiral amines
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：EP2816024B1

  公开（公告）日：2017-08-02
• PREPARATION OF CHIRAL AMIDES AND AMINES
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US20180016224A1

  公开（公告）日：2018-01-18

  This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine sub structure.
• COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES
  申请人：Washington University

  公开号：US20210228591A1

  公开（公告）日：2021-07-29

  The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.
• [EN] COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CELLES-CI POUR LE TRAITEMENT DE PROTÉINOPATHIES
  申请人：UNIV WASHINGTON

  公开号：WO2019204764A1

  公开（公告）日：2019-10-24

  The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.